Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Immunodeficiencies: early-phase trial registry

3 of 9 indexed Immunodeficiencies trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Immunodeficiencies: 9 US clinical trials tracked, 3 recruiting.

Immunodeficiencies is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Hospital of Philadelphia, running 3 of these trials.

Enrollment posture brief

Registry condition immunodeficiencies

OPEN 3 | RECR 33% | LATE 0 | EARLY 5 | RANK #1916 | SPON 3

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Immunodeficiencies (this)33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Immunodeficiencies

Immunodeficiencies lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Immunodeficiencies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Immunodeficiencies is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Immunodeficiencies research.

    Children's Hospital of Philadelphia accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Immunodeficiencies trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.

  4. Immunodeficiencies splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23

Open and recent trials

9 total, page 1 of 1

RECRUITING 2,419 participants

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001281

RECRUITING Early Phase 1 100 participants

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

Children's Hospital of Philadelphia

NCT02356653

RECRUITING NA 30 participants

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

Masonic Cancer Center, University of Minnesota

NCT01666080

ACTIVE NOT RECRUITING Phase 2 75 participants

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

Children's Hospital of Philadelphia

NCT01050855

ACTIVE NOT RECRUITING Phase 2 60 participants

Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies

Children's Hospital of Philadelphia

NCT02990819

COMPLETED 308 participants

COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04852276

COMPLETED 25 participants

Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

University of California, San Francisco

NCT03609827

COMPLETED Phase 1 22 participants

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

Duke University

NCT00744692

COMPLETED Phase 2 20 participants

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

New York Medical College

NCT01049854

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Named interventions

Most-linked intervention names on Immunodeficiencies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Reduced Intensity (Fanconi) Drug
1 trials
Reduced Intensity Drug
1 trials
Full Intensity Drug
1 trials
Full Intensity with TBI Drug
1 trials
Unrelated Umbilical Cord Blood Transplant Biological
1 trials
RIC: Mini Busulfan Drug
1 trials
RIC:Intermediate Campath Drug
1 trials
RIC: Distal Campath Drug
1 trials

US sites by state

Facility locations filed on Immunodeficiencies trials. A trial with sites in several states counts in each.

Pennsylvania 3 trials
Maryland 2 trials
New York 1 trials
North Carolina 1 trials
Minnesota 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Immunodeficiencies page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immunodeficiencies condition card totals 9 registered trials; most-linked intervention Reduced Intensity (Fanconi); top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.